SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

細胞治療バイオマニュファクチャリングの世界市場

Cell Therapy Biomanufacturing: Global Markets

出版年月2024年8月
ページ数112
図表数42
価格タイプシングルユーザライセンス
価格USD 5,500
種別英文調査報告書

世界の細胞治療バイオマニュファクチャリングの市場規模は2029年までに167億ドルに達し、2024年から2029年までに年平均成長率（CAGR）11.5％で成長するとBCC Researchでは予測しています。

BCC Research（BCCリサーチ）「細胞治療バイオマニュファクチャリングの世界市場 – Cell Therapy Biomanufacturing: Global Markets」はバイオマニュファクチャリング（バイオものづくり）による細胞治療の世界市場を詳細に分析予測した市場調査レポートです。

主な調査対象セグメント

  • 地域
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他の地域（RoW）
  • 国
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • シンガポール
    • 米国
    • カナダ
    • メキシコ
    • ドイツ
    • 英国
    • イタリア
    • ロシア
    • スペイン
    • フランス

細胞治療バイオマニュファクチャリング市場予測

Report Overview

This report discusses the key trends shaping the global cell therapy biomanufacturing market, exploring factors that drive or hinder growth while providing valuable insights for stakeholders and potential newcomers. It examines R&D investment, heightened competition, and emerging technologies steering market dynamics. Moreover, the report assesses how advancements, product launches, and governmental initiatives impact future market trajectories. It also scrutinizes corporate actions like mergers, acquisitions, and partnerships. Additionally, the report evaluates the efficacy of various strategies in light of evolving technologies, intensifying competition, and shifting consumer demands.

Report Includes

– 17 data tables and 25 additional tables
– Analysis of the global markets for cell therapy biomanufacturing
– Analyses of global market trends, with market revenue data from 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
– Estimates of the current market size and revenue prospects, along with a market share analysis by product type, application, end user and region
– Facts and figures pertaining to the market dynamics, technological advances, product launches, regulatory scenarios, and the expected impact of macroeconomic factors
– An analysis of patents and emerging technologies
– Overview of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
– An analysis of the industry structure, including companies’ market shares, merger and acquisition activity, and venture funding
– Profiles of the leading companies, including Thermo Fisher Scientific Inc., Bristol-Myers Squibb Co., Lonza, Merck KGaA, andBioSenic SA

Summary

The cell therapy biomanufacturing global market was worth $8.6 billion in 2023. The market is anticipated to achieve a CAGR of 11.5%, resulting in a value of $16.7 billion by the end of 2029. The growth trajectory of the cell therapy biomanufacturing market is underpinned by a convergence of factors that collectively fuel its expansion and innovation. Foremost among these drivers is the escalating prevalence of chronic and degenerative diseases worldwide, accentuating the urgent need for novel therapeutic interventions. This demand is met by the remarkable strides in cell therapy technologies, marked by breakthroughs in cell engineering, gene editing, and manufacturing processes.
These advancements empower researchers and clinicians to effectively harness cells’ regenerative and immunomodulatory properties, offering targeted and personalized treatment modalities for a spectrum of ailments.

Regulatory entities like the FDA and European Medicines Agency (EMA) have championed initiatives to streamline approval processes, catalyzing the development and commercialization of cell-based therapies. Initiatives like the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and the EMA’s Priority Medicines (PRIME) scheme expedite the translation of promising therapies from bench to bedside, fostering a conducive regulatory environment that incentivizes investment and innovation. Indeed, robust investment and funding streams from diverse sources, including venture capital, pharmaceutical conglomerates, and governmental agencies, underscore the burgeoning interest
and confidence in the market’s potential. This financial backing fuels research, development, and clinical trials, propelling the proliferation of novel cell therapy solutions.

Executive Summary

The expanding applications of cell therapy across oncology, regenerative medicine, and immune disorders widen the market’s scope, offering multifaceted avenues for growth and therapeutic advancement. Breakthroughs in induced pluripotent stem cell (iPSC) therapy, mesenchymal stem cell (MSC) therapy, and chimeric antigen receptor (CAR) T-cell therapy underscore the versatility and efficacy of cell-based treatments in addressing an array of medical needs. As the industry evolves, collaborative efforts and strategic partnerships between biopharmaceutical companies, academic institutions, research organizations, and contract manufacturing organizations (CMOs) are pivotal in accelerating innovation, knowledge exchange, and technology transfer. By pooling resources, expertise, and infrastructure, stakeholders harness synergies to navigate regulatory complexities, optimize manufacturing processes, and expedite commercialization timelines. In sum, the cell therapy biomanufacturing market is poised for robust expansion. It is propelled by a confluence of factors that collectively shape its growth trajectory, spur innovation, and pave the way for transformative therapies that promise to improve patient outcomes and revolutionize healthcare standards.

Report Synopsis

Report MetricsDetails
Base year considered2023
Forecast period considered2024-2029
Base year market size$8.6 billion
Market size forecast$16.7 billion
Growth rateCAGR of 11.5% for the forecast period of 2024-2029
Units considered$ Billions
Segments coveredProduct Type, Application Type, and Region
Regions coveredNorth America, Europe, Asia-Pacific, and Rest of the World (RoW)
Countries coveredChina, India, Japan, South Korea, Australia, Singapore, U.S., Canada, Mexico, Germany, U.K., Italy, Russia, Spain, and France
Key Market Drivers
  • Rising Prevalence of Chronic and Degenerative Diseases.
  • Technological Advancements in Bioprocessing.
  • Growing Investment in Research and Development (R&D).
  • Expansion of Cell Therapy Manufacturing Infrastructure
Companies studied
BIOSENICBRISTOL-MYERS SQUIBB CO.
DANAHER CORP.IOVANCE BIOTHERAPEUTICS INC.
LISATA THERAPEUTICSLONZA
MERCK KGAATHERMO FISHER SCIENTIFIC INC.

Table of Contents

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Cell Therapy
Stem Cell Transplantation
Stem Cell Biomanufacturing
Stem Cell Classification Based on Source
Stem Cell Classification Based on Ability to Differentiate
Uses of Stem Cells
Application of Stem Cells
Mechanism of Cell Therapy
Delivery Method of Cell-Based Therapy

Chapter 3 Market Dynamics

Overview
Market Drivers
Rising Prevalence of Chronic and Degenerative Diseases
Growing Investment in R&D
Technological Advancements in Bioprocessing
Expansion of Cell Therapy Manufacturing Infrastructure
Market Restraints
Complexity and Cost of Manufacturing
Supply Chain Issues
Product Stability and Shelf Life
Market Opportunities
Emerging Therapeutic Applications
Patient-Centric Healthcare Models

Chapter 4 Regulatory Structure

Regulatory Authorities
Regulatory Pathways
Quality Assurance
Manufacturing Standards
Global Harmonization Efforts

Chapter 5 Emerging Technologies and Developments

Newest Technologies/Key Developments
Advanced Cell Culture Systems
Genome Editing Technologies
Bioprocessing Innovation
Cell Sorting and Purification
Automation and Robotics
Data Analytics and Machine Learning
Tissue Engineering and Organoid Technologies
Point-of-Care Manufacturing

Chapter 6 Market Segmentation Analysis

Key Market Trends
Cell Therapy Biomanufacturing: Global Markets
Segmentation Breakdown
Market Analysis, by Product Type
Type of Therapy
Source of Cells
Market Analysis, by Application
Skeletal Muscle Repair
Bone Repair
Cancer
Cardiovascular Diseases
Neurological Disorders
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Global Company Ranking
Strategic Analysis
M&A and Venture Funding

Chapter 8 Sustainability in Cell Therapy Biomanufacturing: An ESG Perspective

Environmental Impact
Supply Chain Sustainability
Social Responsibility
Corporate Governance
Product Lifecycle Management
Energy and Water
Recycling
Process Design and Materials
Recycling Single-Use Plastics
Work Environment

Chapter 9 Appendix

Methodology
Sources
Acronyms

Company Profiles

BIOSENIC
BRISTOL-MYERS SQUIBB CO.
DANAHER CORP.
IOVANCE BIOTHERAPEUTICS INC.
LISATA THERAPEUTICS
LONZA
MERCK KGAA
THERMO FISHER SCIENTIFIC INC.

List of Tables

Summary Table A : Global Market for Cell Therapy Biomanufacturing, by Product Type, Through 2029
Summary Table B : Global Market for Cell Therapy Biomanufacturing, by Application, Through 2029
Table 1 : Global Market for Cell Therapy Biomanufacturing, Through 2029
Table 2 : Global Market for Cell Therapy Biomanufacturing, by Product Type, Through 2029
Table 3 : Global Market for Cell Therapy Biomanufacturing, by Application, Through 2029
Table 4 : Global Market for Cell Therapy Biomanufacturing, by Region, Through 2029
Table 5 : North American Market for Cell Therapy Biomanufacturing, by Country, Through 2029
Table 6 : European Market for Cell Therapy Biomanufacturing, by Country, Through 2029
Table 7 : Asia-Pacific Market for Cell Therapy Biomanufacturing, by Country, Through 2029
Table 8 : RoW Market for Cell Therapy Biomanufacturing, by Country, Through 2029
Table 9 : Global Market Rankings of Cell Therapy Biomanufacturing, 2023
Table 10 : Report Sources
Table 11 : Acronyms Used in Cell Therapy Biomanufacturing Market
Table 12 : BioSenic: Company Snapshot
Table 13 : BioSenic: Financial Performance, 2022 and 2023
Table 14 : BioSenic: Product Portfolio
Table 15 : Bristol-Myers Squibb Co.: Company Snapshot
Table 16 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 17 : Bristol-Myers Squibb Co.: Product Portfolio
Table 18 : Bristol-Myers Squibb Co.: News/Key Developments, 2024
Table 19 : Danaher Corp.: Company Snapshot
Table 20 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 21 : Danaher Corp.: Product Portfolio
Table 22 : Danaher Corp.: News/Key Developments, 2023
Table 23 : Iovance Biotherapeutics Inc.: Company Snapshot
Table 24 : Iovance Biotherapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 25 : Iovance Biotherapeutics Inc: Product Portfolio
Table 26 : Iovance Biotherapeutics Inc.: News/Key Developments, 2023
Table 27 : Lisata Therapeutics: Company Snapshot
Table 28 : Lisata Therapeutics: Financial Performance, FY 2022 and 2023
Table 29 : Lisata Therapeutics: Product Portfolio
Table 30 : Lisata Therapeutics: News/Key Developments, 2022
Table 31 : Lonza: Company Snapshot
Table 32 : Lonza Financial Performance, FY 2022 and 2023
Table 33 : Lonza: Product Portfolio
Table 34 : Lonza: News/Key Developments, 2023
Table 35 : Merck KGaA: Company Snapshot
Table 36 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 37 : Merck KgaA: Product Portfolio
Table 38 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 39 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Thermo Fisher Scientific Inc: Product Portfolio
Table 41 : Thermo Fisher Scientific Inc: News/Key Developments, 2023

List of Figures
Summary Figure A : Global Market for Cell Therapy Biomanufacturing, by Product Type, 2021-2029
Summary Figure B : Global Market for Cell Therapy Biomanufacturing, by Application, 2021–2029
Figure 1 : Market Dynamics of Cell Therapy Biomanufacturing
Figure 2 : Global Market Shares of Cell Therapy Biomanufacturing, by Product Type, 2023
Figure 3 : Global Market Shares of Cell Therapy Biomanufacturing, by Application, 2023
Figure 4 : Global Market Shares of Cell Therapy Biomanufacturing, by Region, 2023
Figure 5 : North American Market Shares of Cell Therapy Biomanufacturing, by Country, 2023
Figure 6 : European Market Shares of Cell Therapy Biomanufacturing, by Country, 2023
Figure 7 : Asia-Pacific Market Shares of Cell Therapy Biomanufacturing, by Country, 2023
Figure 8 : RoW Market Shares of Cell Therapy Biomanufacturing, by Country, 2023
Figure 9 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 10 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 11 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 12 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 13 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 14 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 15 : Merck KgaA: Revenue Share, by Country/Region, FY 2023
Figure 16 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 17 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023

バイオ技術の最新記事8件